MSMichael Serbin

Michael Serbin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Serbin has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment

    by Michael Serbin, Connie Marras, Carol Mansfield, Colton Leach, Charles Yonan, Margaret Sheehan, Anne Donnelly, Olga Klepitskaya

    Background: Several adjunctive medications are available to reduce OFF time between levodopa/carbidopa (LD/CD) doses for people with Parkinson’s disease (PD). Objective: To explore how individuals with PD balance benefits and burdens when considering adjunctive medications. Methods: US adults (30– 83 years) with self-reported PD, currently treated with LD/CD, who experienced OFF episodes were recruited through the Fox Insight study to complete a discrete-choice experiment survey. Respondents selected among experimentally designed profiles for hypothetical adjunctive PD treatments that varied in efficacy (additional ON time), potential adverse effects (troublesome dyskinesia, risk of diarrhea, risk of change in bodily fluid color), and dosing frequency or the option “No additional medicine”. Data were analyzed with random-parameters logit models. Results: Respondents (N=480) would require ≥ 60 additional minutes of daily ON time to accept either a 40% risk of change in bodily fluid color or 10 additional minutes with troublesome dyskinesia daily. Respondents would require 40 additional minutes of daily ON time to accept a 10% risk of diarrhea and 22 additional minutes of daily ON time to switch from 1 additional pill each day to 1 pill with each LD/CD dose. On average, respondents preferred adjunctive PD medication over no additional medication. Results predicted that 59.1% of respondents would select a hypothetical treatment profile similar to opicapone, followed by no additional medication (27.5%) and a hypothetical treatment profile similar to entacapone (13.4%). Limitations: The data collected were based on responses to hypothetical choice profiles in the survey questions. The attributes and levels selected for this study were intended to reflect the characteristics of opicapone and entacapone; attributes associated with other adjunctive therapies were not evaluated. Conclusion: Patients with PD expressed interest in adjunctive treatment to increase ON time and would accept reduced ON time to avoid adverse effects. Plain Language Summary: People with Parkinson’s disease may experience OFF time, when their symptoms return between doses of levodopa/carbidopa. Some medicines can reduce OFF time when taken in addition to levodopa/carbidopa. These additional medicines have their own benefits and side effects. In this study, researchers used a survey to understand what side effects people with Parkinson’s disease would accept to have more ON time. Respondents were presented with a series of choices between 2 hypothetical medicines that increased daily ON time or no additional medicine. The medicines were described by 5 features (benefits and side effects). Respondents’ answers to the survey questions allowed researchers to estimate which unwanted side effects people with Parkinson’s disease would accept in exchange for additional ON time. The most important features of a medicine to reduce OFF time, in order, were (1) Lower risk of a change in urine, sweat, or saliva color; (2) Fewer additional minutes with troublesome dyskinesia each day; and (3) Increase in daily ON time. Introducing a 40% risk of change in urine, sweat, or saliva color (from no risk) would require more than 60 minutes of additional daily ON time to offset. An additional 10 minutes of troublesome dyskinesia each day would require more than 60 minutes of additional daily ON time. Introducing a 10% risk of diarrhea (from no risk) would require 40 minutes of additional ON time. Individuals’ preferences for the key features of medications that reduce OFF time for people with Parkinson’s disease should be considered when making treatment decisions.


  • Open Access

    In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103–113

    by Michael Serbin, Charles Yonan, Michael L. Ganz

    Dear Editor,We appreciate the interest from Xue et al. in our cost-effectiveness analysis of valbenazine versus deutetrabenazine for the treatment of tardive dyskinesia (TD) [1], and are gratified ...

  • Open Access

    Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa

    by Ryan N. Hansen, Kangho Suh, Michael Serbin, Chuck Yonan, Sean D. Sullivan

    To assess from a US payer perspective the relative cost-effectiveness of the catechol-O-methyltransferase inhibitors opicapone and entacapone when used adjunctively to levodopa/carbidopa (LD/CD) in...


  • Open Access

    Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia

    by Michael L. Ganz, Ameya Chavan, Rahul Dhanda, Michael Serbin, Charles Yonan

    To evaluate clinical and economic outcomes associated with valbenazine compared with deutetrabenazine in patients with tardive dyskinesia (TD) using a model that accounts for multiple dimensions of...


  • Open Access

    Management and Outcomes for Neovascular Age-Related Macular Degeneration

    by Szilárd Kiss, Joanna Campbell, Arghavan Almony, Vanessa Shih, Michael Serbin, Andrew LaPrise, Charles C. Wykoff